Efficacy and Limitations of Oral Inotropic Agents for the Treatment of Chronic Heart Failure-Reference-Cited by-同舟云学术

Efficacy and Limitations of Oral Inotropic Agents for the Treatment of Chronic Heart Failure

Published:2013 Issue:2 Volume:54 Page:75-81
ISSN:1349-2365
Container-title:International Heart Journal
language:en
Short-container-title:Int. Heart J.

Author:

Murai Koji¹,Seino Yoshihiko²,Kimata Nakahisa²,Inami Toru²,Murakami Daisuke²,Abe Junko²,Yodogawa Kenji²,Maruyama Mitsunori²,Takano Masamichi²,Ohba Takayoshi²,Ibuki Chikao²,Mizuno Kyoichi¹

Affiliation:

1. Department of Cardiology, Nippon Medical School

2. Department of Cardiology, Cardiovascular Center, Nippon Medical School Chiba-Hokusoh Hospital

Publisher

International Heart Journal (Japanese Heart Journal)

Subject

Cardiology and Cardiovascular Medicine,General Medicine

Link

https://www.jstage.jst.go.jp/article/ihj/54/2/54_75/_pdf

Reference38 articles.

1. 1. Kumada T, Kawai C, Sakuma A. Evaluation of new oral dopamine (TA-870) in patients with circulatory failure under drip infusion dopamine - multiclinic doubleblind group comparative study versus dopamine hydrochloride infectable-. Rinsyo to Iyaku 1991; 7: 1521-41. (Japanese)

2. 2. Kubo SH, Gollub S, Bourge R, et al. Beneficial effects of pimobendan on exercise tolerance and quality of life in patients with heart failure. Results of a multicenter trial. The Pimobendan Multicenter Research Group. Circulation 1992; 85: 942-9.

3. 3. Sasayama S, Asanoi H, Kihara Y, et al. Clinical effects of long-term administration of pimobendan in patients with moderate congestive heart failure. Heart Vessels 1994; 9: 113-20.

4. 4. Katz SD, Kubo SH, Jessup M, et al. A multicenter, randomized, double-blind, placebo-controlled trial of pimobendan, a new cardiotonic and vasodilator agent, in patients with severe congestive heart failure. Am Heart J 1992; 123: 95-103.

5. 5. Ikeda M, Sakuma A, Kawai T, Kumada T. Efficacy of new oral inotropic agent “denopamine” (TA-064) for heart failure (double blind study). Igaku no Ayumi 1987; 140: 839-64.

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Reinforcement of pimobendan with guideline-directed medical therapy may reduce the rehospitalization rates in patients with heart failure: retrospective cohort study;Journal of Pharmaceutical Health Care and Sciences;2024-05-20

2. Pimobendan Inhibits HBV Transcription and Replication by Suppressing HBV Promoters Activity;Frontiers in Pharmacology;2022-06-03

3. Effects of Pimobendan on Prolonging Time to Rehospitalization or Frequency of Rehospitalization in Patients with Heart Failure: A Retrospective Cohort Study Using a Medical Administrative Database (PREFER Study);Journal of Health Economics and Outcomes Research;2020-06-23

4. Why has positive inotropy failed in chronic heart failure? Lessons from prior inotrope trials;European Journal of Heart Failure;2019-08-13

5. Contrasting Effects of Inhibition of Phosphodiesterase 3 and 5 on Cardiac Function and Interstitial Fibrosis in Rats With Isoproterenol-Induced Cardiac Dysfunction;Journal of Cardiovascular Pharmacology;2019-03